Prognostic value of nuclear matrix protein expression in localized prostate cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 8, 2012, Pages 1379-1384

  Ricci, Francesco ^a   Rubagotti, Alessandra ^a,b   Zinoli, Linda ^a,b   Mangerini, Rosa ^b   Nuzzo, Pier Vitale ^a   Carmignani, Giorgio ^a,b   Simonato, Alchiede ^a,b   Barboro, Paola ^b   Balbi, Cecilia ^b   Boccardo, Francesco ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Nuclear matrix proteins; Prognosis; Prostate cancer; PSA progression

Indexed keywords

NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 6; NUCLEAR MATRIX PROTEIN 8; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CLUSTER ANALYSIS; DIAGNOSTIC VALUE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CLUSTER ANALYSIS; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84864348572     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1216-0     Document Type: Article

References (21)

1. Alberti I, Barboro P, Barbesino M et al (2000) Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 79(3):471-485
2. Barboro P, Rubagotti A, Boccardo F et al (2005) Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. Anticancer Res 25(6B):3999-4004 (Pubitemid 41665177)
3. Barboro P, Repaci E, Rubagotti A et al (2009) Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer 100(10):1608-1616
4. Boccardo F, Rubagotti A, Carmignani G et al (2003) Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 55(4):259-264 (Pubitemid 36618184)
5. Bomsztyk K, Denisenko O, Ostrowski J (2004) hnRNP K: one protein multiple processes. BioEssays 26(6):629-638 (Pubitemid 38758340)
6. Bostwick DG, Grignon DJ, Hammond ME et al (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):995-1000 (Pubitemid 30602040)
7. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI (2006) Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 95(7):921-927 (Pubitemid 44498109)
8. Chen LC, Hsueh C, Tsang NM et al (2008) Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 14(12):3807-3813
9. CoxDR(1972) Regression models and life tables. JRStat Soc 34:187-220
10. Heukeshoven J, Dernick R (1988) Improved silver staining procedure for fast staining in Phast System Development Unit I. Staining of sodium dodecyl sulfate gels. Electrophoresis 9:28-32
11. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17(3):292-306 (Pubitemid 41646608)
12. Humphrey PA, Vollmer RT (1997) Percentage of carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10:326-333 (Pubitemid 27228880)
13. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
15. Leman ES, Getzenberg RH (2008) Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem 104(6):1988-1993
16. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F (2005) Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95(8):1146-1152 (Pubitemid 40799472)
17. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D (2009) Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 69(6):2210-2218
18. Partin AW, Getzenberg RH, CarMichael MJ et al (1993) Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53:744-746 (Pubitemid 23077855)
19. Peto R, Pike MC, Armitage P et al (1976) Design and analysis of randomised clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612 (Pubitemid 8004970)
20. Peto R, Pike MC, Armitage P et al (1977) Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39 (Pubitemid 8018922)
21. Tefilli MV, Gheiler EL, Tiguert R et al (1999) Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 53:372-377 (Pubitemid 29063329)